No Data
Unveiling 8 Analyst Insights On NovoCure
Throughout the last three months, 8 analysts have evaluated NovoCure (NASDAQ:NVCR), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings, shed
Earnings Call Summary | Novocure(NVCR.US) Q1 2024 Earnings Conference
The following is a summary of the NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript:Financial Performance:NovoCure reported a net revenue of $139 million in Q1 2024, up 13% year-over-year. The
Novocure Is Maintained at Neutral by HC Wainwright & Co.
Novocure Is Maintained at Neutral by HC Wainwright & Co.
NovoCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 70.54% HC Wainwright & Co. $24 → $22 Maintains Neutral 04/10/2024 117.05% Piper Sandler $25 → $
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
Express News | Novocure Limited : H.c. Wainwright Cuts Target Price to $22 From $24
灵巧的托拜厄斯 : 有
Kenneil NugentOP : lol no help